Open AccessLong‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
Author(s) -
Megaro Giacomina,
Miele Evelina,
Spinelli Gian Paolo,
Alessi Iside,
Del Baldo Giada,
Cozza Raffaele,
Russo Ida,
De Pasquale Maria Debora,
Cefalo Maria Giuseppina,
Tomà Paolo,
Carai Andrea,
Di Ruscio Valentina,
De Ioris Maria Antonietta,
Mastronuzzi Angela
Publication year - 2022
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1483
Subject(s) - crizotinib , lung cancer , medicine , alk inhibitor , adenocarcinoma , oncology , oncogene , cancer , cancer research , cell cycle , malignant pleural effusion
Background Lung cancer is the leading cause of cancer‐related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case We present a case of a 17‐year‐old male with metastatic treatment‐naïve ALK‐positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion Crizotinib can be extremely effective in adolescents with treatment‐naïve ALK‐positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.